-
Mashup Score: 13
It’s a phenomenon known by the forbidding name of original antigenic sin, and, in the case of the coronavirus, it prompts a constellation of questions.
Source: Washington PostCategories: Infectious Disease, Latest HeadlinesTweet
-
Mashup Score: 2
Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) is a novel virus that spread worldwide from 2019 causing the Coronavirus disease 19 (COVID-19) pandemic. SARS-CoV-2 infection is characterised by an initial viral phase followed in some patients by a severe inflammatory phase. Importantly, immunocompromised patients may have a prolonged viral phase, shedding infectious viral particles…
Source: NatureCategories: Infectious Disease, Latest HeadlinesTweet-
Recent ECIL 9 recommendations on COVID-19 therapies in patients with hematological malignancies include convalescent plasma. Joins IDSA and AABB in recommending this option. @mtmdphd @DrMJoyner @ACasadevall1 @jwsenefeld https://t.co/RdfsG6LHoq
-
-
Mashup Score: 1Survival in Patients With Hematologic Cancers and COVID-19 - 2 year(s) ago
This cohort study evaluated the association of convalescent plasma treatment with 30-day mortality in hospitalized adults with hematologic cancers and COVID-19.
Source: jamanetwork.comCategories: Infectious Disease, Latest HeadlinesTweet-
"In this cohort study of 966 patients with hematologic cancer and COVID-19...convalescent plasma treatment was associated with a significantly improved 30-day mortality in the 143 individuals who received it." @COVID19nCCC @mtmdphd @hemoncwarner https://t.co/qi0WjTpT10
-
-
Mashup Score: 0Patients Recently Treated for B-lymphoid Malignancies Show Increased Risk of Severe COVID-19 - 2 year(s) ago
Patients treated recently for a B-lymphoid malignancy are shown to have particularly high risks of severe COVID-19 compared to multiple control cohorts of patients with cancer and COVID-19.
Categories: Infectious Disease, Latest HeadlinesTweet-
This is important because "patients treated for B-lymphoid malignancies have an increased risk of severe COVID-19 compared with control populations of patients with non–B-lymphoid malignancies." https://t.co/ylIvHvLtHh @COVID19nCCC
-
-
Mashup Score: 2A RANDOMIZED CONTROLLED CLINICAL TRIAL DEMONSTRATES THAT PLASMA... by Carsten Müller-Tidow - 2 year(s) ago
Access educational materials, eLearning activities, accredited Live webinar sessions with polls and chat on this fast Digital Library and Hybrid Virtual Event Platform powered by MULTILEARNING LMS.
Source: library.ehaweb.orgCategories: Infectious Disease, Latest HeadlinesTweet-
In line with this, a recent RCT finds that "Plasma from convalescent and particularly vaccinated donors improved outcome of COVID-19 patients with an underlying hematological disease /cancer or other reasons of impaired immune response." https://t.co/TSBDF7HzKl
-
-
Mashup Score: 2Convalescent plasma with a high level of virus-specific antibody effectively neutralizes SARS-CoV-2 variants of concern - 2 year(s) ago
Key Points. All of the post-delta COVID-19/post vaccination convalescent plasma effectively neutralizes the omicron and delta variants.High-titer CCP and hyperi
Source: American Society of HematologyCategories: Infectious Disease, Latest HeadlinesTweet-
CCP remains an important therapeutic option as new variants defeat monoclonal antibodies. The polyclonal antibody responses from convalescent + vaccine antibodies in CCP retain the ability to recognize SARS-CoV-2 variants of concern. https://t.co/9utIcsBPdC
-
-
Mashup Score: 3Opinion | COVID Convalescent Plasma Finds a Therapeutic Role - 2 year(s) ago
Growing evidence shows benefits in the immunocompromised
Source: www.medpagetoday.comCategories: Hem/Oncs, Latest HeadlinesTweet-
COVID Convalescent Plasma Finds a Therapeutic Role — Growing evidence shows benefits in the immunocompromised [Jun 19, 2022] @ACasadevall1 @DrJPHenderson @bjgzz @DrMJoyner @ShohamTxID Paneth, Pirofski @medpagetoday https://t.co/WB3hmqkwrn #COVID19CP #COVID19 #IDonc
-
"CCP (COVID Convalescent Plasma) use is now recommended for immunocompromised patients by...the Infectious Diseases Society of America (IDSA) and the Association for the Advancement of Blood and Biotherapies (AABB)." @ACasadevall1 @DrMJoyner @ShohamTxID https://t.co/VNNZ4aRU3l
-
-
Mashup Score: 12National COVID-19 Convalescent Plasma Project - 2 year(s) ago
…
Source: ccpp19.orgCategories: Hem/Oncs, Latest HeadlinesTweet-
RT @ACasadevall1: The COVID-19 Convalescent plasma project (https://t.co/sxhuacKkWp) sends letter to @WHO director signed by >170 physician…
-
RT @ACasadevall1: The COVID-19 Convalescent plasma project (https://t.co/sxhuacKkWp) sends letter to @WHO director signed by >170 physician…
-
-
Mashup Score: 2
On 6 December the World Health Organization recommended against using covid-19 convalescent plasma (CCP) to treat covid-19 based on a statistical summary of selected randomised controlled trials (RCTs). Unfortunately, the WHO summary avoided digging below the surface to ask critical questions about treatment timing, study populations, and antibody titre of the administered CCP in the reviewed…
Source: The BMJCategories: Infectious Disease, Latest HeadlinesTweet-
WHO covid-19 drugs guideline: reconsider using convalescent plasma. Data and rationale for including CP among treatment options has only become stronger since this was written. @WHO @ACasadevall1 @DrMJoyner @ShohamTxID https://t.co/xv99Ely1M6
-
-
Mashup Score: 7
Original Article from The New England Journal of Medicine — Early Outpatient Treatment for Covid-19 with Convalescent Plasma
Source: New England Journal of MedicineCategories: Infectious Disease, Latest HeadlinesTweet-
New in NEJM: Early outpatient treatment with COVID-19 convalescent plasma works in this U.S. RCT. An important option as variants continue to emerge and evade monoclonal antibodies. @COVID19nCCC @mtmdphd @ACasadevall1 @DrMJoyner @ShohamTxID https://t.co/Arlr9yN2bQ
-
Timely, responsible, and interesting (!) science reporting on an immunological concept as variant-adjusted COVID-19 vaccines are on the way. @Carolynyjohnson https://t.co/02WWZDEQeJ